China Shineway Pharmaceutical Group Limited company develops, manufactures, and sells modern Chinese medicines and western pharmaceuticals. Three of its principal products are Xin Nao Qing soft capsules, Qingkailing injection, and Shenmai injection -- the company's production of these three products is the largest in China. Shineway has plans to expand its sales and marketing network, focusing on hospitals and retail pharmacies to expand its market coverage and deepen its market penetration. Chairman Li Zhenjiang and his family control more than 70% of the company.

Arnet Pharmaceutical manufactures private-label nutritional supplements. Arnet Pharmaceutical Corp. products range from daily vitamins and herbal extracts to minerals and amino acids. The company's capabilities include making tablet, capsule, powder, and chewable products. As a contract manufacturer, Arnet will work from customer-provided formulations or formulate products themselves. It also produces blended products such as Osteoporex, a calcium blend to address osteoporosis, and Gluthatione, an antioxidant supplement to increases energy and reduces stress. Founded in 1972, Arnet's customers span across more than 50 countries.

Mannatech was founded in 1993 and is headquartered in Coppell, Texas. Mannatech, Incorporated engages in the development and sale of nutritional supplements, topical and skin care products, and weight-management products worldwide. It offers various nutritional supplements that aid in optimizing overall health and wellness, including health solutions for children, and additional nutrients for specific body systems; optimal weight and fitness products to curb appetite and burn fat, build lean muscle tissue, and support recovery from overexertion; and products to enhance the skin's own natural texture, softness, and elasticity, including damaged areas, as well as to deliver antioxidants to the skin. The company sells its products through a network of independent associates and members in United States, Canada, Australia, the United Kingdom, Japan, New Zealand, the Republic of Korea, Taiwan, Denmark, Germany, South Africa, and Singapore.

ProMetic was founded in 1994. The scientists at ProMetic Life Sciences are meticulous about proteins. The biotech company develops protein technologies for pharmaceutical, diagnostic, and blood and plasma product development. ProMetic's Protein Technologies division licenses its technologies to companies around the globe, who then make their own products. The company's Therapeutics division conducts proprietary drug development programs for blood disease and cancer therapeutics. The company has collaborative agreements with pharmaceutical companies and health organizations such as Abraxis BioScience, Merck Serono, and The American Red Cross.

Ipsen develops pharmaceutical products that target oncology, endocrinology, and neuromuscular disorders. The group additionally markets products to treat gastroenterology, cardiovascular, and cognitive disorders. Ipsen operates research-and-development (R&D) centers in Paris, Boston, Barcelona, and London, which have churned out more than 20 products to the global therapeutic market. Its R&D efforts focus on peptide engineering, protein engineering, medicinal chemistry, and advanced drug delivery. The company markets its products directly as well as through third parties, and has formed strategic development alliances with the likes of Medicis and Applied Biosystems (now part of Life Technologies Corporation).

Auxilium Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Malvern, Pennsylvania. Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to urologists, endocrinologists, orthopedists and select primary care physicians. The Company’s product, Testim, is a topical 1% testosterone once-a-day gel indicated for the treatment of hypogonadism. Hypogonadism is defined as reduced or absent secretion of testosterone which can lead to symptoms such as low energy, loss of libido, adverse changes in body composition, irritability and poor concentration. The product pipeline of the Company includes XIAFLEX (clostridial collagenase for injection) for the treatment of Dupuytren’s contracture (Dupuytren’s), XIAFLEX for the treatment of Peyronie’s disease (Peyronie’s), XIAFLEX for the treatment of Adhesive Capsulitis (frozen shoulder syndrome), AA4010, treatment for overactive bladder using the transmucosal film delivery system and fentanyl pain product using the transmucosal film delivery system.

Amazon Herb sells herbal supplements and other herbal products through a multilevel marketing network under the Rainforest Bio-Energetics brand. The company buys raw materials harvested by indigenous peoples of the rainforests in Peru; it contracts with third parties to make its products, then it packages them under its own label for sale in the US. Its products include herbal nutritional supplements, skin care products, cleaning supplies, and herbal pet-care remedies. Amazon company also sells raw materials in bulk to other manufacturers and donates 10% of its net profits for rain forest preservation.

CEO Alexander Kozak founded D-Pharm Ltd. in 1993. D-Pharm de-velops and de-livers biopharmaceuticals to treat a variety of diseases. The company focuses on discovery and development of lipid-based compounds used primarily against central nervous system disorders. Drugs currently approaching the market include treatments for epilepsy, bipolar disorder, and stroke. The company's pipeline also includes drugs intended to fight Alzheimer's disease, Parkinson's disease, psoriasis, bowel disease, and cancer. D-Pharm partners with other drug companies to bring its treatments to market.

Immtech Pharmaceuticals, Inc. company was founded in 1984 and is based in New York, New York. mmtech Pharmaceuticals, Inc. focuses on the discovery and development of drugs to treat infectious diseases worldwide. The company involves in drug discovery and development programs for hepatitis C and malaria; and provides aromatic cationic pharmaceutical compounds. It also offers assistance to healthcare companies seeking to conduct clinical trials, and manufacture and/or distribute pharmaceutical products in China. In addition, the company involves in investing in metal and mineral assets, primarily tin assets in China.

ReGen Therapeutics did. Its main product is Colostrinin, a polypeptide derived from ovine and bovine colostrum (the first milk produced after the birth of an offspring). The company developed a nutraceutical version of the product that its licensee Metagenics launched in the US under the name CogniSure in 2007. ReGen continues development of a pharmaceutical preparation, as well as a veterinary nutraceutical version for pets. In addition to Colostrinin, ReGen is developing existing insomnia drug Zolpidem as a treatment for head trauma victims. The company's Guildford Clinical Pharmacology subsidiary is a UK-based contract research organization.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.